Revolution Medicines Statistics
Total Valuation
RVMD has a market cap or net worth of $38.37 billion. The enterprise value is $37.73 billion.
| Market Cap | 38.37B |
| Enterprise Value | 37.73B |
Important Dates
The next estimated earnings date is Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RVMD has 212.60 million shares outstanding. The number of shares has increased by 10.96% in one year.
| Current Share Class | 212.60M |
| Shares Outstanding | 212.60M |
| Shares Change (YoY) | +10.96% |
| Shares Change (QoQ) | +0.73% |
| Owned by Insiders (%) | 2.26% |
| Owned by Institutions (%) | 88.01% |
| Float | 194.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 136.17 |
| PB Ratio | 24.84 |
| P/TBV Ratio | 27.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.80, with a Debt / Equity ratio of 0.29.
| Current Ratio | 6.80 |
| Quick Ratio | 6.59 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -38.07 |
Financial Efficiency
Return on equity (ROE) is -76.67% and return on invested capital (ROIC) is -41.78%.
| Return on Equity (ROE) | -76.67% |
| Return on Assets (ROA) | -37.53% |
| Return on Invested Capital (ROIC) | -41.78% |
| Return on Capital Employed (ROCE) | -70.61% |
| Weighted Average Cost of Capital (WACC) | 11.76% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.55M |
| Employee Count | 883 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +375.20% in the last 52 weeks. The beta is 1.38, so RVMD's price volatility has been higher than the market average.
| Beta (5Y) | 1.38 |
| 52-Week Price Change | +375.20% |
| 50-Day Moving Average | 164.32 |
| 200-Day Moving Average | 109.19 |
| Relative Strength Index (RSI) | 55.72 |
| Average Volume (20 Days) | 2,933,830 |
Short Selling Information
The latest short interest is 12.88 million, so 6.06% of the outstanding shares have been sold short.
| Short Interest | 12.88M |
| Short Previous Month | 12.28M |
| Short % of Shares Out | 6.06% |
| Short % of Float | 6.64% |
| Short Ratio (days to cover) | 3.58 |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.13B |
| Operating Income | -1.39B |
| Pretax Income | -1.37B |
| Net Income | -1.37B |
| EBITDA | -1.38B |
| EBIT | -1.39B |
| Earnings Per Share (EPS) | -$7.12 |
Balance Sheet
The company has $1.91 billion in cash and $437.27 million in debt, with a net cash position of $1.47 billion or $6.92 per share.
| Cash & Cash Equivalents | 1.91B |
| Total Debt | 437.27M |
| Net Cash | 1.47B |
| Net Cash Per Share | $6.92 |
| Equity (Book Value) | 1.50B |
| Book Value Per Share | 7.49 |
| Working Capital | 1.68B |
Cash Flow
In the last 12 months, operating cash flow was -$1.06 billion and capital expenditures -$14.26 million, giving a free cash flow of -$1.07 billion.
| Operating Cash Flow | -1.06B |
| Capital Expenditures | -14.26M |
| Depreciation & Amortization | 8.44M |
| Net Borrowing | n/a |
| Free Cash Flow | -1.07B |
| FCF Per Share | -$5.04 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RVMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.96% |
| Shareholder Yield | -10.96% |
| Earnings Yield | -3.50% |
| FCF Yield | -2.73% |
Analyst Forecast
The average price target for RVMD is $200.50, which is 11.11% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $200.50 |
| Price Target Difference | 11.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 23 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |